These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38932369)

  • 1. Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024).
    Riccò M; Cascio A; Corrado S; Bottazzoli M; Marchesi F; Gili R; Giuri PG; Gori D; Manzoni P
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Riccò M; Cascio A; Corrado S; Bottazzoli M; Marchesi F; Gili R; Giuri PG; Gori D; Manzoni P
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.
    Agüera M; Soler-Garcia A; Alejandre C; Moussalam-Merino S; Sala-Castellví P; Pons G; Penela-Sánchez D; González-Grado C; Alsina-Rosell J; Climent C; Esteva C; Fortuny C; de-Sevilla MF; García-García JJ; Brotons P; Balaguer A; Estrada J; Jordan I; Muñoz-Almagro C; Launes C
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14175. PubMed ID: 38899631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis.
    Turalde-Mapili MWR; Mapili JAL; Turalde CWR; Pagcatipunan MR
    Front Pediatr; 2023; 11():1132740. PubMed ID: 37082704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
    Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN;
    N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
    Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38701823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
    Mallah N; Ares-Gómez S; Pardo-Seco J; Malvar-Pintos A; Santiago-Pérez MI; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; González-Pérez JM; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F
    Hum Vaccin Immunother; 2024 Dec; 20(1):2348135. PubMed ID: 38738683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM
    Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children.
    Fly JH; Eiland LS; Stultz JS
    Ann Pharmacother; 2024 Apr; ():10600280241243357. PubMed ID: 38654469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody therapies in respiratory syncytial virus prophylaxis-An umbrella review.
    Kuitunen I; Backman K; Gärdström E; Renko M
    Pediatr Pulmonol; 2024 May; ():. PubMed ID: 38751021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.